Soft tissue sarcomas are genetically heterogeneous and include a broad spectrum of phenotypes. Since the mid-1980s, diagnostic and therapeutic advances have witnessed a considerable improvement in patient outcomes with regard to not only survival but also function and palliation. More recent improvements however have only been incremental.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the molecular pathology underlying sarcoma development, the development of strategies to diagnose, stage, and treat these conditions, and the evaluation of outcomes. We are particularly interested in articles describing the new imaging modalities such as PET and MR spectroscopy; investigatory imaging tools for characterizing cellular behavior and response to treatment; advances in molecular genetics and molecular diagnostics; critical reviews of current surgical approaches to treatment and what paradigm shifts may be required to improve patient outcomes; instruments to measure functional and patient satisfaction outcomes; modalities of radiation therapy with an emphasis on the barriers to improving current care and what strategies may be required to overcome this; and current concepts in chemotherapy and novel strategies designed around small molecules, SiRNA, stem cells, and viral and nonviral gene therapy. Potential topics include, but are not limited to:

• Recent developments in positron emission tomography
• Recent developments in magnetic resonance tomography
• Advanced medical imaging for assessing cellular and molecular interactions
• Amputation or limb salvage surgery—critically analyzing the indications
• Modern concepts in surgical margins including the classification and application of surgical margins
• Concepts in the management of retroperitoneal sarcoma with an emphasis on barriers and facilitators
• The role of radiotherapy in pediatric sarcomas
• The role of radiosensitisers in radiotherapy
• Combination chemotherapy and radiotherapy in sarcomas—what more needs to be done?
• Recent advances in drug delivery systems with regard to targeted therapy
• Role of gene therapy and targeted therapy in sarcoma treatment
• Patient outcomes—limitations and improvements required in current assessment tools
• The place of molecular pathology of the staging of sarcoma. When, why, and why not?

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/srcm/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: